

- 1. What type of breast cancer is Kisqali (ribociclib) FDA indicated to treat?**
 - a. HR+/HER2- premenopausal metastatic breast cancer
 - b. HR+/HER2- postmenopausal metastatic breast cancer
 - c. HR-/HER2+ metastatic breast cancer
 - d. HR+/HER2+ stage II breast cancer
 - 2. Which drug requires pre-treatment with loperamide due to a high incidence of diarrhea?**
 - a. Verzenio (abemaciclib)
 - b. Kisqali (ribociclib)
 - c. Nerlynx (neratinib)
 - d. All of the above
 - 3. Which type of breast cancer is Nerlynx (neratinib) FDA indicated to treat?**
 - a. HR-/HER2+ stage I and II breast cancer
 - b. HR+/HER2- stage I and II breast cancer
 - c. HR-/HER2+ metastatic breast cancer
 - d. HR+/HER2- metastatic breast cancer
 - 4. What is the most prevalent form of hepatitis in the United States?**
 - a. Hepatitis A
 - b. Hepatitis B
 - c. Hepatitis C
 - d. Hepatitis D
 - 5. Which of the following forms of hepatitis does not progress to a chronic infection?**
 - a. Hepatitis B
 - b. Hepatitis D
 - c. Hepatitis C
 - d. Hepatitis E
 - 6. For the treatment of hepatitis C, which newly approved medication is only approved for the re-treatment of hepatitis C in patients that have previously been treated with a NS5A inhibitor?**
 - a. Zepatier
 - b. Eplcusa
 - c. Vosevi
 - d. Mavyret
 - 7. Most newly approved hepatitis C medication regimens include taking one tablet daily. Which new medication requires patients to take 3 tablets per day?**
 - a. Mavyret
 - b. Harvoni
 - c. Zepatier
 - d. Vosevi
 - 8. When is the appropriate time to determine sustained virologic response (SVR), or treatment cure, in patients that have been treated for hepatitis C?**
 - a. 8 weeks after end of therapy
 - b. 12 weeks after end of therapy
 - c. 18 weeks after end of therapy
 - d. 24 weeks after end of therapy
 - 9. Zinbryta (Daclizumab) has a black box warning for which of the following conditions?**
 - a. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults
 - b. Hepatic Injury Including Autoimmune Hepatitis, severe liver injury, and liver failure.
 - c. Reactivation of hepatitis B virus
 - d. Increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke
 - 10. Ocrevus (Ocrelizumab) is the first drug on the market approved to treat which form of MS?**
 - a. Relapsing-Remitting MS (RRMS)
 - b. Secondary progressive MS (SPMS)
 - c. Primary progressive MS (PPMS)
 - d. Progressive-relapsing MS (PRMS)
 - 11. Zinbryta (Daclizumab) is administered via subcutaneous route at what dosing interval?**
 - a. 3 times a week
 - b. Once a week
 - c. Bi-weekly
 - d. Once a month
 - 12. Ocrevus (Ocrelizumab) is administered via IV infusion at what established dosing interval?**
 - a. Every 24 weeks
 - b. Every 2 weeks
 - c. Every 4 weeks
 - d. Every week
-

13. Premedication is required with what medications prior to giving an infusion of Ocrevus (Ocrelizumab)?

- a. A corticosteroid such as methylprednisolone, an antihistamine such as diphenhydramine, and an antipyretic such as acetaminophen if desired
- b. A corticosteroid such as methylprednisolone, an NSAID such as ibuprofen, and an antiemetic such as ondansetron
- c. An antihistamine such as diphenhydramine, an antiemetic such as ondansetron, and an antipyretic such as acetaminophen if desired
- d. An antibiotic such as amoxicillin, an antiemetic such as ondansetron, and an NSAID such as ibuprofen

Participant Information:

AL License # _____

Name _____

Address _____

City _____ State _____ Zip _____

E-mail _____

NABP e-Profile # _____

MM/DD (month/day of birth) _____

How long did it take you to read the article and complete this test?
 _____ hours _____ minutes

CE Assessment Answers
 Please circle your answers (one answer per question)

1.	A	B	C	D
2.	A	B	C	D
3.	A	B	C	D
4.	A	B	C	D
5.	A	B	C	D
6.	A	B	C	D
7.	A	B	C	D
8.	A	B	C	D
9.	A	B	C	D
10.	A	B	C	D
11.	A	B	C	D
12.	A	B	C	D
13.	A	B	C	D

My signature certifies that I have independently taken this CE examination.

Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- | | | | | |
|-----------------------------------|---|---|---|---|
| 1. Overall quality of the article | 1 | 2 | 3 | 4 |
| 2. Relevance to pharmacy practice | 1 | 2 | 3 | 4 |
| 3. Value of the content | 1 | 2 | 3 | 4 |

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives. Agree Disagree
5. The article did not promote a particular product or company. Yes No

Impact of the Activity

The information presented (check all that apply):

6. Reinforced my current practice/treatment habits Will improve my practice/patient outcomes
 Provided new ideas or information I expect to use Adds to my knowledge
7. Will the information presented cause you to make any changes in how you do your job? Yes No
8. How committed are you to making these changes?
 (Not committed) 1 2 3 4 (Very committed).
9. Do you feel future activities on this subject matter are necessary and/or important? Yes No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

- Yes No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.